Ceretype Neuromedicine
Cambridge, US · Founded 2018 · Delaware corporation
Founders & leadership
ES
Emily SternNamed on SEC filing
HP
Hong PanNamed on SEC filing
Board
DS
David SilbersweigBoard director
RL
Richard LipkinBoard director
Reported raises · per SEC filings
Form D private placements$1.8M disclosed across 2 rounds · 2021–2024
▶$400KraisedDec 2025 · 3 investors · BiotechnologyRule 506(b)
▶$400KraisedDec 2025 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David SilbersweigDirector
- Emily SternExecutive Officer, Director
- Richard LipkinDirector
- Offering amount
- $400K
- Amount sold
- $400K
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.4MraisedNov 2021 · 8 investors · Other Health CareRule 506(b)
▶$1.4MraisedNov 2021 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- David SilbersweigDirector
- Emily SternExecutive Officer, Director
- Hong PanDirector
- Offering amount
- $2.5M
- Amount sold
- $1.4M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Ceretype Neuromedicine raised?
- Ceretype Neuromedicine has disclosed $1.8M raised across 2 rounds.
- Where is Ceretype Neuromedicine headquartered?
- Ceretype Neuromedicine is headquartered in Cambridge, US.